AOP Orphan Pharmaceuticals - Articles and news items

Blue & White Pills

AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments

Industry news / 19 June 2015 / AOP Orphan Pharmaceuticals AG

AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+